Get the Stockscreener App
29.52
4.88%
1.375
After Hours:
29.69
0.165
+0.56%
Cogent Biosciences Inc stock is traded at $29.52, with a volume of 2.78M.
It is up +4.88% in the last 24 hours and down -9.82% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$28.15
Open:
$28.33
24h Volume:
2.78M
Relative Volume:
1.28
Market Cap:
$5.12B
Revenue:
$23.16M
Net Income/Loss:
$-354.30M
P/E Ratio:
-11.70
EPS:
-2.5234
Net Cash Flow:
$-286.27M
1W Performance:
-1.85%
1M Performance:
-9.82%
6M Performance:
-18.71%
1Y Performance:
+78.18%
1-Day Range:
$28.33
$29.78
1-Week Range:
$27.73
$31.07
52-Week Range:
$13.78
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
29.52 | 5.12B | 23.16M | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Taking options instead of cash, a Cogent Biosciences (COGT) director receives a 759-option award. - Stock Titan
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
A drug trial found responses in 65% of patients. The FDA will review it. - Stock Titan
Cogent Biosciences Announces FDA Acceptance of New Drug - GlobeNewswire
Cogent Biosciences Stock Price Forecast. Should You Buy COGT? - StockInvest.us
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences (COGT) Edges Higher as Buyers Defend Key Support ZoneExtension Target - siam.in
Cogent Biosciences Enters Commercial Supply Agreement With Hovione FarmaCiencia - marketscreener.com
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com India
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com Australia
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com Nigeria
$100 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Benzinga
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com South Africa
Cogent Biosciences director Arlene Morris sells $1.69m shares By Investing.com - Investing.com Canada
Cogent Biosciences Insider Sold Shares Worth $1,689,493, According to a Recent SEC Filing - marketscreener.com
Cogent Biosciences (COGT) director sells 45K shares in 10b5-1 plan - stocktitan.net
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress - Barchart.com
Cogent Biosciences (COGT) Slides 6.5% to $34.67 as Support and Resistance Levels Come into FocusETF Premium Discount - dars.gov.et
Cogent Biosciences Inc. (COGT) Peer Comparison – Compare with Others - Value Research
Cogent Biosciences (NASDAQ: COGT) director schedules option-led stock sale years ahead - Stock Titan
Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat (NASDAQ:COGT) - Seeking Alpha
Cogent (COGT) Earnings Report: EPS Falls Short of Its Estimate in the Current Update; After Results: Shares Fall 0.91% in the Latest SessionAnalyst Earnings Estimate - vinanet.vn
Cogent (COGT) Earnings Reading: The Available Earnings Metric Delivers a Miss on the Day; Price Move - vinanet.vn
What Cogent Biosciences (COGT)'s Widening Net Losses Mean For Shareholders - simplywall.st
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences (COGT) Q2 Update Highlights Valuation Challenges Amid Strong Cash Reserves - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - Sahm
COGT Maintained by Piper Sandler -- Price Target Raised to $55 - GuruFocus
Has Cogent Biosciences (COGT) Run Too Far After Wider Losses? - simplywall.st
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - simplywall.st
Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next - webull.com
Discipline and Rules-Based Execution in COGT Response - Stock Traders Daily
Bank of America Corp DE Has $40.18 Million Stock Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences | ARS: Annual Report to Security Holders - Moomoo
Deerfield group discloses 2.88% Cogent Biosciences (COGT) position in amended 13G - Stock Titan
Cogent Biosciences (COGT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
COGT Maintains Buy Rating by Guggenheim -- Price Target Raised t - GuruFocus
Guggenheim raises Cogent stock price target to $52 on FDA decisions - Investing.com
Tema ETFs LLC Acquires 64,898 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cogent Biosciences (COGT) Edges Higher to $38.98, Holding Ground Between Key Technical LevelsSmart Beta Flow - vinanet.vn
Cogent Biosciences (NASDAQ:COGT) Shares Down 5.7%Should You Sell? - MarketBeat
Cogent Biosciences (COGT) Slides 6.81% to $38.70 as Biotech Risk-Off IntensifiesLate Stage Breakouts - vinanet.vn
Cogent Biosciences Q2 Loss Widens - Moomoo
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results - Investing News Network
Cogent BiosciencesMay Offer Up To $400 Million In Common Stock Through Guggenheim Securities - TradingView
Cogent Biosciences (COGT) files prospectus for $400M at-the-market stock program - Stock Titan
Cogent Biosciences (NASDAQ: COGT) details cash runway and bezuclastinib FDA timelines - Stock Titan
Cogent Biosciences (NASDAQ:COGT) Shares Gap DownTime to Sell? - MarketBeat
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cogent Biosciences Inc Stock (COGT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Arlene | Director |
Aug 27 '26 |
Sale |
37.12 |
45,510 |
1,689,493 |
0 |
| ARLENE MORRIS | Director |
Aug 27 '26 |
Proposed Sale |
36.72 |
45,510 |
1,671,127 |
0 |
| Fairmount Healthcare Fund II L | Director |
Mar 31 '26 |
Proposed Sale |
34.66 |
7,000,000 |
242,620,000 |
0 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Sale |
34.66 |
7,000,000 |
242,620,000 |
5,503,418 |
| Fairmount Funds Management LLC | Director |
Jan 22 '26 |
Sale |
36.40 |
3,500,000 |
127,400,000 |
5,503,418 |
| Fairmount Healthcare Fund II L | Director |
Jan 22 '26 |
Proposed Sale |
36.40 |
3,500,000 |
127,400,000 |
0 |
| Kearns Evan | Chief Legal Officer |
Dec 26 '25 |
Sale |
38.70 |
65,000 |
2,515,500 |
109,398 |
| Green John L. | Chief Financial Officer |
Dec 26 '25 |
Sale |
38.68 |
77,000 |
2,978,360 |
131,834 |
| Sachs Jessica | Chief Medical Officer |
Dec 26 '25 |
Sale |
38.70 |
82,642 |
3,198,245 |
133,938 |
| Robinson John Edward | Chief Scientific Officer |
Dec 26 '25 |
Sale |
38.74 |
90,000 |
3,486,600 |
140,002 |
2.18%
0.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):